Genzyme touts Renagel data

Genzyme Corporation said its three-year study of 2,100 dialysis patients showed that its Renagel drugs is better than calcium-based phosphate binders at prolonging patients' lives. The drug was particularly effective in those patients treated with Renagel for two years or more, and in those 65 or older.

- read this release for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.